#Strata oncology trial
The platform, which integrates comprehensive genomic profiling and highly quantitative RNA expression profiling, enables comprehensive molecular insights from a single, minute tumor tissue specimen. An Observational Study Profiling Biospecimens from Cancer Patients to Screen for Molecular Alterations. The Strata Trial (STR-001-001) has been initiated by Strata Oncology to evaluate the clinical benefit of systematic comprehensive genomic profiling for participants with advanced cancer using real-world data and endpoints, while assessing the proportion of participants available for clinical trials and approved targeted therapies in advanced and/or aggressive cancers. Led by Dan Rhodes, Ph.D., co-founder and Chief Executive Officer, Strata Oncology is a precision oncology company involved in expanding its comprehensive genomic and transcriptomic profiling platform to deliver a portfolio of treatment selection tests for solid tumors. The proceeds will be used to accelerate the development of Strata Oncology’s personalized minimal residual disease (MRD) assay for early-stage cancers and advance its pipeline of novel RNA-based treatment selection tests for solid tumors. Strata Oncology’s existing investors, including Pfizer Ventures, Merck Global Health Innovation Fund, Arboretum Ventures, Deerfield Management, Baird Capital and Renaissance Venture Capital Fund also participated in the financing, which brings the company’s total raised to date to over $130m since inception. Wellington Management led the financing and was joined by other new investors including Cormorant Asset Management, Monashee Investment Management and Highside Capital Management.
#Strata oncology series
If a physician orders the StrataNGS® test for comprehensive molecular profiling, no additional tissue is required to perform StrataEXP.Strata Oncology, Inc., an Ann Arbor, Mich.-based precision oncology company advancing molecular indications for cancer therapies, raised $90m in Series C financing. We currently provide StrataEXP results as supplemental information in order to offer physicians broader molecular insights into each patient’s cancer.
StrataEXP uses RNA-sequencing to generate quantitative expression results from 10 expression biomarkers, which are targeted by multiple approved and investigational therapies, including antibodies, antibody drug conjugates, radiopharmaceuticals and immunotherapies. The 46 gene panel used for the assay was developed from data generated in conjunction with the StrataNGS test. StrataEXP is a laboratory-developed multi-gene expression test. It partners with healthcare systems that send their. Single-/multi-nucleotide variants (SNVs), short insertions and deletions (indels), copy number alterations (CNAs amplifications and deep deletions), microsatellite instability (MSI) status, gene fusions, and tumor mutation burden (TMB) are assessed simultaneously. Strata Oncology is a precision oncology company enabling molecular indications for cancer therapeutics.
The 429-gene assay is performed on co-isolated RNA and DNA. StrataNGS is a comprehensive genomic profiling (CGP) test that features the lowest tumor tissue requirements in the industry (>2mm2 surface area). Our ability to provide deep cancer insights from minute tumor tissue samples ensures that more of your patients have the opportunity to benefit from precision medicine. The Strata Oncology tumor profiling platform combines DNA and RNA sequencing to deliver comprehensive cancer insights to help providers manage patients with advanced cancer.
Comprehensive treatment insights for more patients using less tissue.
0 kommentar(er)
